BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA)
Subscribe to RSS: 
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop and procure medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security through its programmatic initiatives.
-
CORE SERVICES
BARDA supports a number of core services to assist the production of required products, in a manner that is timely, reliable and cost effective.
-
CBRN PROGRAMS
The Pandemic and All Hazards Preparedness Act (PAHPA) established BARDA as the focal point within HHS for the advanced development and acquisition of medical countermeasures to protect the American civilian population against CBRN and naturally occurring threats to public health.
-
PANDEMIC INFLUENZA
BARDA uses a comprehensive portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic flu, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures and to build and sustain their domestic manufacturing infrastructure.
-
INNOVATION
BARDA's Strategic Science and Technology Division helps bring innovation to our programs. The innovation programs identify and support the advancement of platform technologies that enhance capabilities for the development and manufacturing of medical countermeasures that focus on biodefense, pandemic influenza and other emerging infectious diseases.
-
STOCKPILE BUILDING
Congress seeks to improve our Nation's emergency preparedness with Project BioShield, which provides the government with the ability to develop, acquire, stockpile, and make available the medical countermeasures needed to protect the U.S. population against a public health threat.
BARDA funding and acquisitions bridge the "valley of death" characterizing the late stages of product development. BARDA's support ensures continuity of funding for medical countermeasures developed by industry or emerging from the basic research and preclinical development activities sponsored by the National Institutes of Health (NIH). In procuring medical countermeasures for the Strategic National Stockpile, BARDA enhances the capabilities of the Centers for Disease Control and Prevention (CDC) to organize an effective response.
BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield. In addition, BARDA manages the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and is a key partner in implementing the PHEMCE strategies.
To learn more about requirements setting for medical countermeasure research and development click here.
Newsroom
- October 10, 2018 - HHS expands corporate partnership to protect against health security threats
- October 02, 2018 - HHS seeks to repurpose burn dressings for radiation emergencies
- October 01, 2018 - HHS, Genentech join forces on medicines to combat influenza, other health security threats
- September 25, 2018 - HHS partners to develop faster tests to identify bacterial infections
- September 25, 2018 - HHS sponsors new formulation of world’s first approved smallpox drug
Publications
National Biodefense Strategy 2018
It is a vital interest of the United States to manage the risk of biological incidents. In today’s interconnected world, biological incidents have the potential to cost thousands of American lives, cause significant anxiety, and greatly impact travel and trade...
PHEMCE Strategy and Implementation Plan 2017-2018
The U.S. continues to face a range of serious threats to its health security from the unintentional release or deliberate use of chemical, biological, radiological, and nuclear (CBRN) agents, as well as naturally occurring emerging infectious diseases (EID), including pandemic influenza...BARDA Project Listing
View maps and project details for BARDA projects with work performed inside and outside of the United States.
View Project MapsPopular Resources
Industry partners are encouraged to visit the BARDA Broad Agency Announcement and sign up for a BARDA TechWatch meeting.